Natural Product (NP) Details
General Information of the NP (ID: NP7746) | |||||
---|---|---|---|---|---|
Name |
Omega-3 PUFAs
|
||||
Species Origin | phytoplankton environmental sample ... | Click to Show/Hide | |||
phytoplankton environmental sample | |||||
Disease | Periodontal disease [ICD-11: DA0C] | Phase 4 | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Naproxen | Osteoarthritis | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | VCAM1 | Molecule Info |
Pathway MAP
|
|
Biological
Regulation |
Decrease | Serum TG | ||||
In-vivo Model | Clinical trial | |||||
Experimental
Result(s) |
Combining NX with omega-3 PUFAs increases their effectiveness in reducing serum TG and favorably altering AT gene expression and plasma bile acid profile. | |||||
Proanthocyanidins | Atherosclerosis | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Down-regulation | Bifidobacterium secretion | ||||
Up-regulation | Lactobacillus secretion | |||||
In-vivo Model | A total of twenty-eight female Wistar-Kyoto rats aged 8-10 weeks were used in this study. | |||||
Experimental
Result(s) |
Combined supplementation of Omega-3 PUFAs and proanthocyanidins from grape seed counteracts the effects of the Omega-3 PUFAs on health-promoting lactobacillus and bifidobacterium, and on acetic acid, while maintaining their beneficial effects on cholesterolemia. |